hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== ColdFusion and .NET === ColdFusion 8 natively supports .NET within the CFML syntax. ColdFusion developers can simply call any .NET assembly without needing to recompile or alter the assemblies in any way. Data types are automatically translated between ColdFusion and .NET (example: .NET DataTable → ColdFusion Query). A unique feature for a Java EE vendor, ColdFusion 8 offers the ability to access .NET Assemblies remotely through proxy (without the use of .NET Remoting). This allows ColdFusion users to leverage .NET without having to be installed on a Windows operating system.
Castor oil is well known as a source of ricinoleic acid, a monounsaturated, 18-carbon fatty acid. Among fatty acids, ricinoleic acid is unusual in that it has a hydroxyl functional group. Because of this functional group, ricinoleic acid is more polar than most fatty acid. The alcohol group underpins the conversion of ricinoleic acid into sebacic acid and 2-octanol. Because of its ricinoleic acid content, castor oil is a valuable chemical in feedstocks, commanding a higher price than other seed oils. As an example, in July 2007, Indian castor oil sold for about USD $0.90 per kilogram ($0.41/lb), whereas U.S. soybean, sunflower, and canola oils sold for about $0.30 per kilogram ($0.14/lb).
Bioassessment A decline in a macrophyte community may indicate water quality problems and changes in the ecological status of the water body. Such problems may be the result of excessive turbidity, herbicides, or salination. Conversely, overly high nutrient levels may create an overabundance of macrophytes, which may in turn interfere with lake processing. Macrophyte levels are easy to sample, do not require laboratory analysis, and are easily used for calculating simple abundance metrics.
Analysis of mitochondrial DNA by German herpetologist Wolfgang Wüster and colleagues in 2005 found the Papuan and nominate subspecies to be very similar genetically; however, their distinct coloration and limited sampling led Wüster to refrain from lumping the subspecies into a single taxon. Raymond Hoser described Oxyuranus scutellatus barringeri from a specimen collected from the Mitchell Plateau, however Wüster declared this a nomen nudum as the author did not explain how it was distinct. Hoser replied that it was distinct on the basis of DNA and distribution, and published it under a different subspecific name—O. scutellatus andrewwilsoni—in 2009, reporting it had a more rounded head and rougher neck scales than other subspecies of coastal taipan, and lacked a lighter colour on the snout. Kinghorn gave it the name "giant brown snake" in 1930, before Thomson introduced the term taipan in 1933. It is commonly called the coastal taipan, common taipan, or simply taipan. The New Guinea subspecies is known as the Papuan taipan. Local names in New Guinea include dirioro by the people of Parama village near the Fly River, and gobari near the Vailala River.
Sources: en.wikipedia.org
The paraxial and other regions of the mesoderm are thought to be specified by bone morphogenetic proteins (BMPs) along an axis spanning from the center to the sides of the body. Members of the fibroblast growth factor family also play an important role, as does the Wnt pathway. In particular, Noggin, a downstream target of the Wnt pathway, antagonizes BMP signaling, forming boundaries where antagonists meet and limiting this signaling to a particular region of the mesoderm. Together, these pathways provide the initial specification of the paraxial mesoderm and maintain this identity. This specification process has now been fully recapitulated in vitro with the formation of paraxial mesoderm progenitors from pluripotent stem cells, using a directed differentiation approach. The tissue undergoes convergent extension as the primitive streak regresses, or as the embryo gastrulates. The notochord extends from the base of the head to the tail; with it extend thick bands of paraxial mesoderm. As the primitive streak continues to regress, somites form from the paraxial mesoderm by "budding off" rostrally. In certain model systems, it has been shown that the daughter cells of stem cell-like progenitor cells which come from the primitive streak or site of gastrulation migrate out and localize in the posterior paraxial mesoderm. As the primitive streak regresses and somites bud off anteriorly, new cells derived from these stem-cell like precursors constantly enter the posterior end of the paraxial mesoderm.
==== Electron-detachment dissociation ==== Electron-detachment dissociation (EDD) is a method for fragmenting anionic species in mass spectrometry. It serves as a negative counter mode to electron capture dissociation. Negatively charged ions are activated by irradiation with electrons of moderate kinetic energy. The result is ejection of electrons from the parent ionic molecule, which causes dissociation via recombination.
Caldo de cardán (lit. 'driveshaft broth'), known by the moniker "The Viagra of the Andes", is a Bolivian cuisine bull penis and testicle soup. A speciality of El Alto and La Paz, the soup is eaten for its perceived benefits as a stimulant, aphrodisiac and hangover cure, and for pain relief. Caldo de cardán typically features many other meats, such as beef tendon, ribs, and ch'arki, as well as hardboiled eggs, potatoes, rice, onions and llajua. The soup is simmered for over ten hours and typically served on weekends, particularly Sunday morning, at a high temperature.
Only the last display in the daisy-chain does not need to support the feature specifically or have a DP output port. DisplayPort 1.1 displays can also be connected to MST hubs, and can be part of a DisplayPort daisy-chain if it is the last display in the chain. The host system's software also needs to support MST for hubs or daisy-chains to work. While Microsoft Windows environments have full support for it, Apple operating systems currently do not support MST hubs or DisplayPort daisy-chaining as of macOS 10.15 ("Catalina"). DisplayPort-to-DVI and DisplayPort-to-HDMI adapters/cables may or may not function from an MST output port; support for this depends on the specific device. MST is supported by USB Type-C DisplayPort Alternate Mode, so standard DisplayPort daisy-chains and MST hubs do function from Type-C sources with a simple Type-C to DisplayPort adapter.
Methenamine is provided in the form of 500 and 1,000 mg oral tablets. It is available both alone and in combination with the nonsteroidal anti-inflammatory drug (NSAID) sodium salicylate. Other combinations with other drugs, such as phenazopyridine, are also available. Methenamine is provided pharmaceutically alone as the hippuric acid (methenamine hippurate) and mandelic acid (methenamine mandelate) salts. The free base and other salts, including anhydromethylencitrate and sulfosalicylate, have also been marketed in some countries. Methenamine mandelate is provided as an enteric coated tablet and is taken four times daily, whereas methenamine hippurate is available only in non-coated tablet form and is taken twice daily. Non-coated methenamine tablets can have a chemical taste described as sweet, sour, and/or metallic. Methenamine is available both by prescription (by itself) and over the counter (in combinations). Over-the-counter formulations in combination with sodium salicylate (162.5 mg) contain a lower amount of methenamine of 162 mg methenamine free base per tablet compared to prescription formulations and are taken three times daily.
Sources: en.wikipedia.org
It is not only a mother who may breastfeed a child. Parents may hire another person to do so (a wet nurse), or may share childcare with another mother (cross-nursing). Both of these were common throughout history. It remains popular in some developing nations, including those in Africa, for more than one woman to breastfeed a child. Shared breastfeeding is a risk factor for HIV infection in infants. Shared nursing can sometimes provoke negative social reactions in the English-speaking world.
The lucky survivor model (cluster ionization mechanism) postulates that analyte molecules are incorporated in the matrix maintaining the charge state from solution. Ion formation occurs through charge separation upon fragmentation of laser ablated clusters. Ions that are not neutralized by recombination with photoelectrons or counter ions are the so-called lucky survivors. The thermal model postulates that the high temperature facilitates the proton transfer between matrix and analyte in melted matrix liquid. Ion-to-neutral ratio is an important parameter to justify the theoretical model, and the mistaken citation of ion-to-neutral ratio could result in an erroneous determination of the ionization mechanism. The model quantitatively predicts the increase in total ion intensity as a function of the concentration and proton affinity of the analytes, and the ion-to-neutral ratio as a function of the laser fluences. This model also suggests that metal ion adducts (e.g., [M+Na]+ or [M+K]+) are mainly generated from the thermally induced dissolution of salt. The matrix-assisted ionization (MAI) method uses matrix preparation similar to MALDI but does not require laser ablation to produce analyte ions of volatile or nonvolatile compounds. Simply exposing the matrix with analyte to the vacuum of the mass spectrometer creates ions with nearly identical charge states to electrospray ionization. It is suggested that there are likely mechanistic commonality between this process and MALDI.
These symbols are also valid for RNA, except with U (uracil) replacing T (thymine). Apart from adenine (A), cytosine (C), guanine (G), thymine (T) and uracil (U), DNA and RNA also contain bases that have been modified after the nucleic acid chain has been formed. In DNA, the most common modified base is 5-methylcytidine (m5C). In RNA, there are many modified bases, including pseudouridine (Ψ), dihydrouridine (D), inosine (I), ribothymidine (rT) and 7-methylguanosine (m7G). Hypoxanthine and xanthine are two of the many bases created through mutagen presence, both of them through deamination (replacement of the amine-group with a carbonyl-group). Hypoxanthine is produced from adenine, and xanthine is produced from guanine. Similarly, deamination of cytosine results in uracil.
Following four months Transport was absorbed into the new "monster ministry" of the Department for the Environment, under Heseltine's ally Peter Walker. Heseltine was still responsible for transport, but also for local government reform, covered in the Local Government Act 1972. Redcliffe-Maude's proposals for unitary councils (i.e. merging the two layers of county and borough/district councils) were abandoned. Many historic counties were abolished. Large Metropolitan counties were created around the big cities, but many smaller cities lost their county borough status. One such was Plymouth, the eastern suburbs of which lay in Heseltine's seat of Tavistock. Plymouth opinion was particularly angry that education was now to be run by Devon County Council in Exeter, 40 miles away. Heseltine declined to support a campaign by Plymouth MP Dame Joan Vickers to create a Tamarside Metropolitan county, and was rebuked by Sir Henry Studholme, his predecessor as MP for Tavistock, for declining to support (on the grounds that as minister he might have to adjudicate any dispute) Plymouth Council's attempt to buy more land near Sparkwell to develop light industry under its control.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.